Autologous stem cell transplantation for multiple myeloma (MM) results in effective cytoreduction but patients subsequently relapse. A promising area of investigation is the development of cancer vaccines that educate host immunity to selectively target and eliminate MM cells and can be used to eradicate residual disease following autologous stem cell transplantation. We have developed a cancer vaccine in which dendritic cells (DC) are fused to autologous tumor cells resulting in the presentation of multiple tumor antigens with the capacity to elicit a broad anti-tumor response. In a clinical trial of patients with advanced MM, vaccination with autologous DC/MM fusions induced anti-tumor immunity in a majority of patients, and disease stabilization ranging from 10 weeks to 36 months. In an ongoing trial of MM patients undergoing DC/tumor fusion vaccination in conjunction with stem cell transplantation, we have demonstrated a marked expansion of myeloma reactive T cells with the concomitant eradication of post-transplant residual disease following vaccination. To overcome the intrinsic immunosuppressive environment and regulatory T ceils that limit vaccine response, we are developing strategies to incorporate adoptive immunotherapy with MM reactive T cell clones. One approach is the use of vaccination prior to stem cell collection such that educated lymphocytes are infused at the time of transplant and further expanded in vivo by post-transplant vaccination. Alternatively, adoptive immunotherapy may be further optimized by ex-vivo generation of MM specific T cells with an activated phenotype. We have found that ligation of CD3/CD28 following ex vivo stimulation with DC/MM fusion vaccine results in the dramatic expansion of activated tumor reactive T cells while minimizing the presence of regulatory T cells. Our hypothesis is that combining transplant mediated cytoreduction and regulatory T cell depletion with the infusion of activated tumor reactive lymphocytes and boosting vaccination with DC/MM fusions offers the ideal platfomn for optimized cellular immunotherapy in MM. To address this hypothesis the Specific Aims are: 1) To evaluate toxicity, cellular and humoral antitumor immunity, and clinical response of a combined DC/MM vaccination and adoptive transfer of in vivo primed T cells;2) To optimize strategies for the ex vivo expansion of myeloma specific T cells using sequential stimulation with DC/MM fusions and anti-CD3/CD28 ex vivo;and 3) To define the toxicity, immunologic response and clinical effect of ex vivo generated and expanded myeloma specific T cells administered in conjunction with pre and post-transplant vaccination with DC/MM fusions.

Public Health Relevance

Multiple myeloma is an incurable malignancy. The proposed work involves the further development of a vaccine for the treatment of multiple myeloma. These studies have the potential to advance therapy for patients with this disease.

National Institute of Health (NIH)
National Cancer Institute (NCI)
Research Program Projects (P01)
Project #
Application #
Study Section
Special Emphasis Panel (ZCA1-RPRB-J)
Project Start
Project End
Budget Start
Budget End
Support Year
Fiscal Year
Total Cost
Indirect Cost
Dana-Farber Cancer Institute
United States
Zip Code
Hu, Y; Song, W; Cirstea, D et al. (2015) CSNK1?1 mediates malignant plasma cell survival. Leukemia 29:474-82
Bae, J; Prabhala, R; Voskertchian, A et al. (2015) A multiepitope of XBP1, CD138 and CS1 peptides induces myeloma-specific cytotoxic T lymphocytes in T cells of smoldering myeloma patients. Leukemia 29:218-29
Suzuki, R; Hideshima, T; Mimura, N et al. (2015) Anti-tumor activities of selective HSP90?/? inhibitor, TAS-116, in combination with bortezomib in multiple myeloma. Leukemia 29:510-4
Tian, Ze; D'Arcy, Padraig; Wang, Xin et al. (2014) A novel small molecule inhibitor of deubiquitylating enzyme USP14 and UCHL5 induces apoptosis in multiple myeloma and overcomes bortezomib resistance. Blood 123:706-16
Campigotto, Federico; Weller, Edie (2014) Impact of informative censoring on the Kaplan-Meier estimate of progression-free survival in phase II clinical trials. J Clin Oncol 32:3068-74
Samur, Mehmet Kemal (2014) RTCGAToolbox: a new tool for exporting TCGA Firehose data. PLoS One 9:e106397
Cottini, Francesca; Hideshima, Teru; Xu, Chunxiao et al. (2014) Rescue of Hippo coactivator YAP1 triggers DNA damage-induced apoptosis in hematological cancers. Nat Med 20:599-606
Kronke, Jan; Udeshi, Namrata D; Narla, Anupama et al. (2014) Lenalidomide causes selective degradation of IKZF1 and IKZF3 in multiple myeloma cells. Science 343:301-5
Hideshima, Hiromasa; Yoshida, Yasuhiro; Ikeda, Hiroshi et al. (2014) IKK? inhibitor in combination with bortezomib induces cytotoxicity in breast cancer cells. Int J Oncol 44:1171-6
Tai, Y-T; Landesman, Y; Acharya, C et al. (2014) CRM1 inhibition induces tumor cell cytotoxicity and impairs osteoclastogenesis in multiple myeloma: molecular mechanisms and therapeutic implications. Leukemia 28:155-65

Showing the most recent 10 out of 135 publications